A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
收藏NIAID Data Ecosystem2026-05-01 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/61464
下载链接
链接失效反馈官方服务：
资源简介：
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.
创建时间：
2023-07-15
